BCMA-CAR-NK 92 cells are being used in the relapsed and refractory multiple myeloma patients with BCMA (B-cell maturation antigen) expression in Suzhou Hospital Affiliated to Nanjing Medical University with the purpose of enabling NK-92 cells by CARs to recognize and kill MM cells through targeting BCMA (NCT03940833). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.